This hypothesis is supported, for instance, by the higher effectiveness of treatment with anti CTLA-4 therapeutic mAbs in cancers characterized by a high mutational load, likely to result in a higher expression of mutated proteins potentially recognized as “non-self” by the adaptive immune system (70). Here, CTLA4 is linked to cancer.